These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 23769790)
1. Exacerbation of central serous chorioretinopathy following PASCAL photocoagulation. Yang HS; Park SH Can J Ophthalmol; 2013 Jun; 48(3):e42-3. PubMed ID: 23769790 [No Abstract] [Full Text] [Related]
2. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab. Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857 [TBL] [Abstract][Full Text] [Related]
3. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? Hwang H; Kim JY; Kim KT; Chae JB; Kim DY Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559 [TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy. Pikkel J; Rumelt S Eur J Ophthalmol; 2012; 22(3):488-91. PubMed ID: 21928270 [TBL] [Abstract][Full Text] [Related]
9. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy. Okamoto M; Matsuura T; Ogata N Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Lee JY; Chae JB; Yang SJ; Kim JG; Yoon YH Acta Ophthalmol; 2011 May; 89(3):e293-4. PubMed ID: 20346078 [No Abstract] [Full Text] [Related]
11. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820 [TBL] [Abstract][Full Text] [Related]
12. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases. Donati MC; Miele A; Abbruzzese G; Giuntoli M; Giansanti F; Menchini U Eur J Ophthalmol; 2013; 23(2):267-70. PubMed ID: 23225087 [TBL] [Abstract][Full Text] [Related]
13. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677 [TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Kim GA; Rim TH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS Eye (Lond); 2015 Jun; 29(6):732-40; quiz 741. PubMed ID: 25952951 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy. Ernst BJ; García-Aguirre G; Oliver SC; Olson JL; Mandava N; Quiroz-Mercado H Acta Ophthalmol; 2012 Nov; 90(7):e573-4. PubMed ID: 22405048 [No Abstract] [Full Text] [Related]
17. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Nomura Y; Obata R; Yanagi Y Jpn J Ophthalmol; 2012 May; 56(3):245-9. PubMed ID: 22526618 [TBL] [Abstract][Full Text] [Related]